TORONTO -- An investigational antibody drug, designed to cross the blood-brain barrier (BBB) to eliminate amyloid-beta ...

In a Phase Ib/IIa trial, 91% of patients receiving the highest dose of trontinemab were amyloid negative after seven months ...

Long-term extension data presented at the Alzheimer's Association International Conference showed amyloid plaque ...

Without the receptor, ADGRG1, the microglia barely nibbled on the toxic protein. Using a mouse model of Alzheimer's disease, ...

Trontinemab is one of a class of new medicines aimed at clearing amyloid plaques. The new findings from phase two trials ...

Scientists at UCSF have uncovered how certain immune cells in the brain, called microglia, can effectively digest toxic ...

UCSF researchers have identified ADGRG1, a microglial receptor that helps clear amyloid beta plaques in Alzheimer’s disease.

Trontinemab’s Phase Ib/IIa Brainshuttle™ AD study continues to show rapid and robust clearance of amyloid plaques, with 91% ...

Microglia, a type of brain immune cell, can gobble up amyloid beta protein, which clumps together into toxic aggregates ...

Families across Georgia are finding new hope in the fight against Alzheimer’s disease, thanks to promising treatments at ...

Higher brain copper levels are linked to slower cognitive decline and lower Alzheimer’s pathology, shows a 20-year study.